Health Care [ 2/12 ] | Biotechnology [ 3/73 ]
NASDAQ | Common Stock
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States.
The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 clinical trial development.
It is also developing Torudokimab (ZB-880), a monoclonal antibody that neutralizes IL-33 to prevent ST2-dependent and ST2-independent inflammation, which has completed Phase 1/2 clinical studies; and Crebankitug (ZB-168), a monoclonal antibody that binds and neutralizes the IL-7 receptor alpha chain that impact on diseases driven by IL-7 and thymic stromal lymphopoietin immune pathways, which has completed Phase 1/1b clinical studies.
Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 14, 25 | -0.17 Increased by 0.00% | -0.30 Increased by +43.33% |
| May 8, 25 | -0.19 Decreased by -850.00% | -0.29 Increased by +34.48% |
| Mar 25, 25 | -0.10 Increased by +47.37% | -0.24 Increased by +58.33% |
| Nov 7, 24 | -0.26 Decreased by -44.44% | -0.13 Decreased by -100.00% |
| Aug 13, 24 | -0.17 Increased by +87.02% | -0.15 Decreased by -13.33% |
| May 9, 24 | -0.02 Increased by +99.27% | -0.23 Increased by +91.30% |
| Mar 28, 24 | -0.19 Decreased by -575.00% | -0.23 Increased by +17.39% |
| Nov 13, 23 | -0.18 Decreased by -700.00% | -0.25 Increased by +28.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 0.00 Decreased by N/A% | -15.99 M Decreased by -26.27% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -17.44 M Decreased by -2.29 K% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 2.00 K Increased by +N/A% | -13.63 M Decreased by -60.80% | Decreased by -681.25 K% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -20.70 M Decreased by -150.33% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -12.67 M Increased by +62.77% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -730.00 K Increased by +92.39% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -8.47 M Decreased by -668.87% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -8.27 M Decreased by -794.05% | Decreased by N/A% Decreased by N/A% |